Published on

ELI LILLY PROPOSES SETTLEMENT OF ITS TESTOSTERONE LITIGATION AFTER ITS MADE UP ILLNESS OF “LOW-T”

Eli Lilly, the manufacturer of Axiron Gel, is working on a master settlement plan to end its litigation for claims against it due to the increased risk of heart attack, stroke, blood clots and sudden death.   Axiron was approved to treat hypogonadism, a serious medical condition causing severe dysfunction of the testicles in men.  However, Eli Lilly and other drug companies marketing the products off label not only for hypogonadism but also for a condition they allegedly invented and call “Low T.”

Lawsuits accuse  the drug companies of marketing the products as safe and effective for this off-label use, when in fact, the products have been shown to  provide little or no benefit for men without hypogonadism and the drugs can cause heart attack, stroke, blood clots and sudden death —  all serious medical problems for which the companies allegedly did not adequately warn patients or doctors about.

Eli Lilly did not face a jury on these cases, however, its competitor Abbie-Vie for its sale of Androgel face a jury twice.  The jury awarded punitive damages of $150 million and $140 million due to their conduct.  Punitive damages are not awarded to compensate the victim, but rather as a punishment for outrageous conduct.

The settlement is not yet finalized, however, it may soon be.  If you or a loved one has suffered a heart attack, a stroke or death while taking Axiron or Androgel, you may be entitled to compensation, but you should act now.  Once a master settlement is approved, compensation on individual cases is very difficult and often not attainable.  If you would like to file a case or would like more information, contact us.